Navigation Links
Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
Date:9/2/2013

LEX Peyronie's program and are committed to working with the FDA while they complete their review. We are continuing to prepare for commercialization in Peyronie's disease, assuming FDA approval by the revised PDUFA date." According to the Company, the FDA has not requested for additional clinical studies to be performed prior to the revised PDUFA action date. The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/AUXL]

--

Accuray Incorporated Research Report

On August 27, 2013, Accuray Incorporated (Accuray) reported its financial results for Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). The Company's net revenue declined 15.6% YoY to $84.9 million during the quarter and dropped 22.8% YoY to $316 million for full-year FY 2013. Net loss attributable to stockholders was $18.7 million, or $0.25 per diluted share, in Q4 FY 2013, compared to net loss of $20.3 million, or $0.28 per diluted share, in Q4 FY 2012. For full-year FY 2013, net loss attributable to stockholders was $103.2 million, or $1.41 per diluted share, compared to net loss of $72.0 million, or $1.02 per diluted share, in full-year FY 2012. Commenting on the results, Joshua H. Levine, President and Chief Executive Officer of Accuray, said, "This was the second quarter in which we have shown growth and improvement in new order volume, driven by the actions we have taken to improve the commercial focus and execution of our business. I am encouraged that while we have seen improved commercial momentum, at the same time we have also reduced operating expenses, resulting in significantly lower operating losses and cash usage." The Full Research Report on Accuray Incorporated - including full detaile
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Verum.de Exhibits at Outsourcing in Clinical Trials Southern California
2. Leading the Site CTMS Market: Clinical Conductor CTMS Reaches 1,600 Sites
3. Clinovo Sponsors Outsourcing in Clinical Trials Southern California Conference 2013, in La Jolla (CA), September 24-25
4. Mytrus Electronic Informed Consent System Selected for 2013 Product Leadership Award in Clinical Trials
5. In Vitro Safety Screening for Clinical Liabilities, New Life Science Webinar hosted by Xtalks
6. ACRES Launches Global Clinical Research Network Technology Platform
7. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
8. Indiana University Contracts with Virtify for Clinical Trial Disclosure Solutions
9. LabAnswer and OpGen Implement the STARLIMS Cloud Platform to Support OpGenā€™s CLIA Certified Clinical Services Laboratory in Under Four Months
10. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
11. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... , , , ... the world,s leading research and advisory firms focusing on pharmaceutical ... lost substantial patient share in second- and third-line therapy since ... is most likely attributed to the publication of the ENHANCE ...
... , EMERYVILLE, Calif., Aug. 12 Neurobiological Technologies, ... it has entered into an agreement to terminate its license ... Medical Center Corporation (CMCC). Pursuant to the termination of ... final payment to NTI in satisfaction of all its royalty ...
... ... and lost each month, though the average of new jobs in the industry remains at 20,000 ... the U.S. However, companies ancillary to health care, such as insurers, are feeling the economic pinch ... (Vocus) August 12, ...
Cached Biology Technology:Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... is the first handbook of its kind, introducing ... microcirculation. Clearly structured throughout, this book is ... on microcirculation imaging. , Author Professor Martin J. ... explores everything from basic research to medical applications. ...
... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the 2012 Genetics Society of America (GSA) Yeast Genetics ... 31 August 5, 2012. These awards are ... postdoctorates and scientists into the mainstream of the basic ...
... from the fields of social, biological and medical science ... to discuss how they can cooperate to improve our ... influence how our genetic inheritance is expressed (epigenetics). This ... epigenetic changes have for such key social policy issues ...
Cached Biology News:World experts meet in Edinburgh to consider how life experiences impact on our genes 2
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
... I Large (Klenow) Fragment, Exonuclease Minus, is ... the 5´→3´ and the 3´→5´ exonuclease activities ... I (1,2). It is used for random ... amplification (5). Klenow Fragment, Exonuclease Minus, will ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: